Neuropharmacology in Pediatric Brain Injury: A Review

PM and R

Volumn 2, Issue 12, 2010, Pages 1127-1140

  Pangilinan, Percival H ^a   Giacoletti Argento, Angela ^a   Shellhaas, Renee ^a   Hurvitz, Edward A ^a   Hornyak, Joseph Edward ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMANTADINE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DESIPRAMINE; DOXEPIN; ETIRACETAM; KETAMINE; LORAZEPAM; MEMANTINE; METHYLPHENIDATE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NORTRIPTYLINE; PHENYTOIN; PLACEBO; PRAMIPEXOLE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLPIDEM;

ACROMEGALY; AGITATION; AKATHISIA; ALZHEIMER DISEASE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CEREBROVASCULAR DISEASE; CHILDHOOD DISEASE; CHILDHOOD INJURY; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSCIOUSNESS DISORDER; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; EPILEPTIC STATE; ESSENTIAL TREMOR; EXTRAPYRAMIDAL SYMPTOM; GROWTH DISORDER; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; INDUCED HYPOTENSION; INFLUENZA; INJURY SEVERITY; INSOMNIA; LONG TERM CARE; MIGRAINE; NARCOLEPSY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PANIC; PARKINSONISM; PATIENT MONITORING; PEPTIC ULCER; PERSISTENT VEGETATIVE STATE; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATION DEPRESSION; RESPIRATORY ARREST; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP AROUSAL DISORDER; SPASTICITY; SYNCOPE; TACHYCARDIA; THYROTOXICOSIS; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; AROUSAL; BACLOFEN; BENZODIAZEPINES; BRAIN INJURIES; CHILD; COGNITION DISORDERS; DEPRESSION; DOPAMINE AGONISTS; GABA AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; PSYCHOMOTOR AGITATION;

EID: 78649955059     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2010.07.007     Document Type: Review

References (117)

1. Schneier A.J., Shields B.J., Hostetler S.G., Xiang H., Smith G.A. Incidence of pediatric traumatic brain injury and associated hospital resource utilization in the United States. Pediatrics 2006, 118:483-492.
2. Forum on Child and Family Statistics, Accessed August 1, 2010. http://childstats.gov.
3. Crooks C.Y., Zumsteg J.M., Bell K.R. Traumatic brain injury: a review of practice management and recent advances. Phys Med Rehabil Clin N Am 2007, 18:681-710. vi.
4. Hugh J., Raghupathi R. New concepts in treatment of pediatric traumatic brain injury. Anesthesiol Clin 2009, 27:213-240.
5. Priestley T., Horne A.L., McKernan R.M., Kemp J.A. The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures. Brain Res 1990, 531:183-188.
6. Ikonomidou C., Turski L. Prevention of trauma-induced neurodegeneration in infant and adult rat brain: glutamate antagonists. Metab Brain Dis 1996, 11:125-141.
7. Rao V.L., Dogan A., Todd K.G., Bowen K.K., Dempsey R.J. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res 2001, 911:96-100.
8. Pohl D., Bittigau P., Ishimaru M.J., et al. N-methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci U S A 1999, 96:2508-2513.
9. Muir K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006, 6:53-60.
10. Ikonomidou C., Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol 2002, 1:383-386.
11. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nat Neurosci 2002, 5(Suppl):1039-1042.
12. Fujiki M., Kubo T., Kamida T., et al. Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury. J Clin Neurosci 2008, 15:791-796.
13. Fujiki M., Kobayashi H., Uchida S., Inoue R., Ishii K. Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats. Brain Res 2005, 1043:236-241.
14. Statler K.D. Pediatric posttraumatic seizures: epidemiology, putative mechanisms of epileptogenesis and promising investigational progress. Dev Neurosci 2006, 28:354-363.
15. Adelson P.D., Bratton S.L., Carney N.A., et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 19. The role of anti-seizure prophylaxis following severe pediatric traumatic brain injury. Pediatr Crit Care Med 2003, 4(Suppl):S72-S75.
16. Chiaretti A., De Benedictis R., Polidori G., Piastra M., Iannelli A., Di Rocco C. Early post-traumatic seizures in children with head injury. Childs Nerv Syst 2000, 16:862-866.
17. Szaflarski J.P., Sangha K.S., Lindsell C.J., Shutter L.A. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010, 12:165-172.
18. Wang H., Gao J., Lassiter T.F., et al. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 2006, 5:71-78.
19. Klitgaard H., Pitkanen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003, 5(Suppl 1):S9-S16.
20. Alves O.L., Doyle A.J., Clausen T., Gilman C., Bullock R. Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. Ann N Y Acad Sci 2003, 993:25-34. discussion 48-53.
21. Hoover R.C., Motta M., Davis J., et al. Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma 2004, 21:501-512.
22. Tang V., Warden J., Cullen N., Rutledge E. Topiramate in traumatic brain injury: adverse effects on cognitive function. J Head Trauma Rehabil 2007, 22:409-410.
23. Dolberg O.T., Barkai G., Gross Y., Schreiber S. Differential effects of topiramate in patients with traumatic brain injury and obesity-a case series. Psychopharmacology (Berl) 2005, 179:838-845.
24. McDonald C.M., Jaffe K.M., Fay G.C., et al. Comparison of indices of traumatic brain injury severity as predictors of neurobehavioral outcome in children. Arch Phys Med Rehabil 1994, 75:328-337.
25. Fridman E.A., Calvar J., Bonetto M., et al. Fast awakening from minimally conscious state with apomorphine. Brain Inj 2009, 23:172-177.
26. Aoki F.Y., Sitar D.S. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988, 14:35-51.
27. Green L.B., Hornyak J.E., Hurvitz E.A. Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study. Am J Phys Med Rehabil 2004, 83:893-897.
28. McMahon M.A., Vargus-Adams J.N., Michaud L.J., Bean J. Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. Am J Phys Med Rehabil 2009, 88:525-532.
29. Patrick P.D., Blackman J.A., Mabry J.L., Buck M.L., Gurka M.J., Conaway M.R. Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol 2006, 21:879-885.
30. Patrick P.D., Buck M.L., Conaway M.R., Blackman J.A. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj 2003, 17:497-506.
31. Passler M.A., Riggs R.V. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil 2001, 82:311-315.
32. Hornyak J.E., Nelson V.S., Hurvitz E.A. The use of methylphenidate in paediatric traumatic brain injury. Pediatr Rehabil 1997, 1:15-17.
33. Clauss R.P., Güldenpfennig W.M., Nel H.W., Sathekge M.M., Venkannagari R.R. Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J 2000, 90:68-72.
34. Clauss R., Nel W. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation 2006, 21:23-28.
35. Cohen S.I., Duong T.T. Increased arousal in a patient with anoxic brain injury after administration of zolpidem. Am J Phys Med Rehabil 2008, 87:229-231.
36. Whyte J., Myers R. Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil 2009, 88:410-418.
37. Kawecki Z., Kwiatkowski S., Grzegorzewski P., Szlachta Jezioro I. Sudden improvement of all neurological functions after general anesthesia and two-day intrathecal infusion of baclofen in a child with primary brain-stem injury [in Polish]. Przegl Lek 2007, 64(Suppl 2):13-14.
38. Sarà M., Pistoia F., Mura E., Onorati P., Govoni S. Intrathecal baclofen in patients with persistent vegetative state: 2 hypotheses. Arch Phys Med Rehabil 2009, 90:1245-1249.
39. Sarà M., Sacco S., Cipolla F., et al. An unexpected recovery from permanent vegetative state. Brain Inj 2007, 21:101-103.
40. Taira T., Hori T. Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl 2007, 97:227-229.
41. Lequerica A.H., Rapport L.J., Loeher K., Axelrod B.N., Vangel S.J., Hanks R.A. Agitation in acquired brain injury: impact on acute rehabilitation therapies. J Head Trauma Rehabil 2007, 22:177-183.
42. Fugate L.P., Spacek L.A., Kresty L.A., Levy C.E., Johnson J.C., Mysiw W.J. Definition of agitation following traumatic brain injury: I. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil 1997, 78:917-923.
43. Mysiw W.J., Jackson R.D., Corrigan J.D. Amitriptyline for post-traumatic agitation. Am J Phys Med Rehabil 1988, 67:29-33.
44. Fleminger S., Greenwood R.J., Oliver D.L. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev 2006, (4). CD003299.
45. Francisco G.E., Walker W.C., Zasler N.D., Bouffard M.H. Pharmacological management of neurobehavioural sequelae of traumatic brain injury: a survey of current physiatric practice. Brain Inj 2007, 21:1007-1014.
46. Goldstein L.B. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry 1995, 58:753-755.
47. Wroblewski B.A., Joseph A.B. The use of intramuscular midazolam for acute seizure cessation or behavioral emergencies in patients with traumatic brain injury. Clin Neuropharmacol 1992, 15:44-49.
48. Perna R. Benzodiazepines and antipsychotics: cognitive side effects. J Head Trauma Rehabil 2004, 19:516-518.
49. Goldstein L.B. Basic and clinical studies of pharmacologic effects on recovery from brain injury. J Neural Transplant Plast 1993, 4:175-192.
50. Cotton B.A., Snodgrass K.B., Fleming S.B., et al. Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. J Trauma 2007, 62:26-33. discussion 33-35.
51. Brooke M.M., Patterson D.R., Questad K.A., Cardenas D., Farrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil 1992, 73:917-921.
52. Massagli T.L. Neurobehavioral effects of phenytoin, carbamazepine, and valproic acid: implications for use in traumatic brain injury. Arch Phys Med Rehabil 1991, 72:219-226.
53. Kossoff E.H., Bergey G.K., Freeman J.M., Vining E.P. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001, 42:1611-1613.
54. Bootsma H.P., Aldenkamp A.P., Diepman L., et al. The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia 2006, 47(Suppl 2):24-27.
55. Chatham Showalter P.E., Kimmel D.N. Agitated symptom response to divalproex following acute brain injury. J Neuropsychiatry Clin Neurosci 2000, 12:395-397.
56. Wroblewski B.A., Joseph A.B., Kupfer J., Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj 1997, 11:37-47.
57. Chatham-Showalter P.E. Carbamazepine for combativeness in acute traumatic brain injury. J Neuropsychiatry Clin Neurosci 1996, 8:96-99.
58. Azouvi P., Jokic C., Attal N., Denys P., Markabi S., Bussel B. Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial. Brain Inj 1999, 13:797-804.
59. Pachet A., Friesen S., Winkelaar D., Gray S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Inj 2003, 17:715-722.
60. Cipriani A., Santilli C., Furukawa T.A., et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009, (2). CD006532.
61. Fugate L.P., Spacek L.A., Kresty L.A., Levy C.E., Johnson J.C., Mysiw W.J. Measurement and treatment of agitation following traumatic brain injury: II. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil 1997, 78:924-928.
62. Reinhard D.L., Whyte J., Sandel M.E. Improved arousal and initiation following tricyclic antidepressant use in severe brain injury. Arch Phys Med Rehabil 1996, 77:80-83.
63. Jackson R.D., Corrigan J.D., Arnett J.A. Amitriptyline for agitation in head injury. Arch Phys Med Rehabil 1985, 66:180-181.
64. Turner-Stokes L., Hassan N., Pierce K., Clegg F. Managing depression in brain injury rehabilitation: the use of an integrated care pathway and preliminary report of response to sertraline. Clin Rehabil 2002, 16:261-268.
65. Silver J.M., McAllister T.W., Arciniegas D.B. Depression and cognitive complaints following mild traumatic brain injury. Am J Psychiatry 2009, 166:653-661.
66. Ashman T.A., Cantor J.B., Gordon W.A., et al. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury. Arch Phys Med Rehabil 2009, 90:733-740.
67. Lee H., Kim S.W., Kim J.M., Shin I.S., Yang S.J., Yoon J.S. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Hum Psychopharmacol 2005, 20:97-104.
68. Fann J.R., Uomoto J.M., Katon W.J. Sertraline in the treatment of major depression following mild traumatic brain injury. J Neuropsychiatry Clin Neurosci 2000, 12:226-232.
69. Kant R., Smith-Seemiller L., Zeiler D. Treatment of aggression and irritability after head injury. Brain Inj 1998, 12:661-666.
70. Meythaler J.M., Depalma L., Devivo M.J., Guin-Renfroe S., Novack T.A. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj 2001, 15:321-331.
71. Zafonte R.D., Cullen N., Lexell J. Serotonin agents in the treatment of acquired brain injury. J Head Trauma Rehabil 2002, 17:322-334.
72. Müller U., Murai T., Bauer-Wittmund T., von Cramon D.Y. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999, 13:805-811.
73. Sloan R.L., Brown K.W., Pentland B. Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj 1992, 6:315-319.
74. Kline A.E., Hoffman A.N., Cheng J.P., Zafonte R.D., Massucci J.L. Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. Neurosci Lett 2008, 448:263-267.
75. Kline A.E., Massucci J.L., Zafonte R.D., Dixon C.E., DeFeo J.R., Rogers E.H. Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma. Crit Care Med 2007, 35:919-924.
76. Hoffman A.N., Cheng J.P., Zafonte R.D., Kline A.E. Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits. Life Sci 2008, 83:602-607.
77. Stanislav S.W. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj 1997, 11:335-341.
78. Elovic E.P., Lansang R., Li Y., Ricker J.H. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil 2003, 18:177-195.
79. Gardner D.M., Baldessarini R.J., Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005, 172:1703-1711.
80. Horacek J., Bubenikova-Valesova V., Kopecek M., et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
81. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
82. Wilkinson R., Meythaler J.M., Guin-Renfroe S. Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj 1999, 13:1025-1031.
83. Kadyan V., Colachis S.C., Depalma M.J., Sanderson J.D., Mysiw W.J. Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation. Brain Inj 2003, 17:631-637.
84. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome. Med Clin North Am 1993, 77:185-202.
85. Bellamy C.J., Kane-Gill S.L., Falcione B.A., Seybert A.L. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma 2009, 66:954-958.
86. Stanislav S.W., Childs A. Evaluating the usage of droperidol in acutely agitated persons with brain injury. Brain Inj 2000, 14:261-265.
87. Michals M.L., Crismon M.L., Roberts S., Childs A. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 1993, 13:198-203.
88. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
89. Noé E., Ferri J., Trénor C., Chirivella J. Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia. Behav Neurol 2007, 18:7-11.
90. Scott L.K., Green R., McCarthy P.J., Conrad S.A. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. J Neurosurg Pediatr 2009, 3:484-487.
91. Kim E., Bijlani M. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. J Neuropsychiatry Clin Neurosci 2006, 18:547-549.
92. Oster T.J., Anderson C.A., Filley C.M., Wortzel H.S., Arciniegas D.B. Quetiapine for mania due to traumatic brain injury. CNS Spectr 2007, 12:764-769.
93. Daniels J.P., Felde A. Quetiapine treatment for mania secondary to brain injury in 2 patients. J Clin Psychiatry 2008, 69:497-498.
94. Wilson M.S., Gibson C.J., Hamm R.J. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil 2003, 82:871-879.
95. Levin H.S., Hanten G. Executive functions after traumatic brain injury in children. Pediatr Neurol 2005, 33:79-93.
96. Arnsten A.F.T. Stimulants: therapeutic Actions in ADHD. Neuropsychopharmacology 2006, 31:2376-2383.
97. Gualtieri C.T., Evans R.W. Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury. Brain Inj 1988, 2:273-290.
98. Williams S.E., Ris M.D., Ayyangar R., Schefft B.K., Berch D. Recovery in pediatric brain injury: is psychostimulant medication beneficial?. J Head Trauma Rehabil 1998, 13:73-81.
99. Mahalick D.M., Carmel P.W., Greenberg J.P., et al. Psychopharmacologic treatment of acquired attention disorders in children with brain injury. Pediatr Neurosurg 1998, 29:121-126.
100. Wilens T.E., Biederman J., Wong J., Spencer T.J., Prince J.B. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol 2000, 10:217-222.
101. Wilens T.E., Waxmonsky J., Scott M., et al. An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005, 15:947-955.
102. Doyle R.L., Frazier J., Spencer T.J., Geller D., Biederman J., Wilens T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord 2006, 9:543-549.
103. Bourgeois J.A., Bahadur N., Minjares S. Donepezil for cognitive deficits following traumatic brain injury: a case report. J Neuropsychiatry Clin Neurosci 2002, 14:463-464.
104. Foster M., Spiegel D.R. Use of donepezil in the treatment of cognitive impairments of moderate traumatic brain injury. J Neuropsychiatry Clin Neurosci 2008, 20:106.
105. Ballesteros J., Güemes I., Ibarra N., Quemada J.I. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J Head Trauma Rehabil 2008, 23:171-180.
106. Tenovuo O. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:61-67.
107. Fann J.R., Katon W.J., Uomoto J.M., Esselman P.C. Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. Am J Psychiatry 1995, 152:1493-1499.
108. Himanen L., Portin R., Tenovuo O., et al. Attention and depressive symptoms in chronic phase after traumatic brain injury. Brain Inj 2009, 23:220-227.
109. Koponen S., Taiminen T., Portin R., et al. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry 2002, 159:1315-1321.
110. Jorge R.E., Robinson R.G., Moser D., Tateno A., Crespo-Facorro B., Arndt S. Major depression following traumatic brain injury. Arch Gen Psychiatry 2004, 61:42-50.
111. Arciniegas D.B., Silver J.M. Pharmacotherapy of posttraumatic cognitive impairments. Behav Neurol 2006, 17:25-42.
112. Fann J.R., Uomoto J.M., Katon W.J. Cognitive improvement with treatment of depression following mild traumatic brain injury. Psychosomatics 2001, 42:48-54.
113. Wroblewski B.A., McColgan K., Smith K., Whyte J., Singer W.D. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990, 10:124-128.
114. Warden D.L., Gordon B., McAllister T.W., et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma 2006, 23:1468-1501.
115. Bessette R.F., Peterson L.G. Fluoxetine and organic mood syndrome. Psychosomatics 1992, 33:224-226.
116. Horsfield S.A., Rosse R.B., Tomasino V., Schwartz B.L., Mastropaolo J., Deutsch S.I. Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. Int J Psychiatry Med 2002, 32:337-344.
117. Schmitt J.A., Kruizinga M.J., Riedel W.J. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001, 15:173-179.